AI Article Synopsis
- Major depression significantly affects quality of life and is often treated with selective serotonin reuptake inhibitors (SSRIs) like escitalopram, which is effective and has a favorable safety profile.
- The study aims to assess escitalopram's therapeutic potential for managing major depressive disorder (MDD) and panic disorders through a review of clinical and comparative trial data.
- Findings indicate that escitalopram is a reliable first-line treatment for MDD, highlighting its effectiveness, safety, and recent advancements for future research.
Article Abstract
Background: Major depression is a debilitating, sometimes fatal disorder, deteriorating the quality of life and well-being. Escitalopram showed highly selective and dose-dependent inhibitory activity on human serotonin transport. Selective serotonin reuptake inhibitors (SSRIs) are the first-line drugs to manage major depressive disorder (MDD).
Objective: The objective of this study is to explore the therapeutic potential of escitalopram, a clinically approved drug to manage MDD and panic disorders.
Methods: It emphasizes comparative and clinical trial studies with several pharmacological targets reviewed from the data available on PubMed, Science Direct, Clinicaltrails.gov, and from many reputed foundations.
Results: To highlight the clinical efficacy, safety, recent development, and stable formulation of escitalopram with an increased bioavailability profile. Evidence-based on the available clinical and pharmacoeconomic data, escitalopram represents an effective first-line treatment option for MDD patients.
Conclusion: The present review highlights the placebo-controlled clinical studies and the recent development that can be helpful for further research perspectives.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1871527321666220301122807 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!